Fampridine-SR Update - for the proposed indication of improvement of walking ability in people with multiple sclerosis (MS).
Posted Nov 17 2009 10:20pm
Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR
Company to Host Investor Conference Call onThursday, October 15at8:00 a.m.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Oct. 9, 2009--Acorda Therapeutics, Inc.today announced that theU.S. Food and Drug Administration(FDA) has posted on its website briefing documents for thePeripheral and Central Nervous System Drugs Advisory Committeemeeting to review Acorda’s New Drug Application (NDA) for Fampridine-SR for the proposed indication of improvement of walking ability in people with multiple sclerosis (MS). The Prescription Drug User Fee Act (PDUFA) action date for the Fampridine-SR NDA isOctober 22, 2009.
The Advisory Committee meeting is scheduled for8:00 a.m. ETonWednesday, October 14th. The briefing materials can be accessed at: